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Summary
Objective: Human and Organizational Factors (HOF) studies in 
health technology involve human beings and thus require Institu-
tional Review Board (IRB) approval. Yet HOF studies have specific 
constraints and methods that may not fit standard regulations 
and IRB practices. Gaining IRB approval may pose difficulties for 
HOF researchers. This paper aims to provide a first overview of 
HOF study challenges to get IRB review by exploring differences 
and best practices across different countries. 
Methods: HOF researchers were contacted by email to provide a 
testimony about their experience with IRB review and approval. 
Testimonies were thematically analyzed and synthesized to 
identify and discuss shared themes. 
Results: Researchers from seven European countries, Argentina, 
Canada, Australia, and the United States answered the call. Four 
themes emerged that indicate shared challenges in legislation, IRB 
inefficiencies and inconsistencies, general regulation and costs, 
and lack of HOF study knowledge by IRB members. We propose a 
model for IRB review of HOF studies based on best practices. 
Conclusion: International criteria are needed that define low 
and high-risk HOF studies, to allow identification of studies that 
can undergo an expedited (or exempted) process from those that 
need full IRB review. Enhancing IRB processes in such a way 
would be beneficial to the conduct of HOF studies. Greater knowl-
edge and promotion of HOF methods and evidence-based HOF 
study designs may support the evolving discipline. Based on 
these insights, training and guidance to IRB members may be 
developed to support them in ensuring that appropriate ethical 
issues for HOF studies are considered.
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1   Introduction
After the horrors of World War Two, the Dec-
laration of Helsinki was widely adopted as a 
guide to conduct research on human beings 
[1]. Even if it initially explicitly targeted 
medical research, it is recognized that this 
declaration concerns also social sciences, 
and any research involving humans or infor-
mation/data about them. Nowadays, various 
national and international scientific societies 
have adopted, extended, and updated this 
declaration to help researchers conduct 
studies in an ethical way (e.g. American 
Psychology Association [2]). 
As for medical informatics, the American 
Medical Informatics Association (AMIA) 
acknowledges that the Declaration of 
Helsinki “should guide all human subject 
research, including research that involves 
users of informatics tools and interventions 
as human subjects (e.g., workflow analysis 
studies, clinical decision support systems 
analysis, patient care innovations analysis, 
etc.)” [3]. Therefore, human and organiza-
tional factors (HOF)-related studies in the 
field of medical informatics must comply 
with the Declaration of Helsinki.
One of the principles of the Declaration 
of Helsinki is that research protocols must be 
reviewed by an independent committee prior 
to initiation. Institutional Review Boards 
(IRB, also known as institutional research 
board, ethical appraisal board, committee of 
protection of persons, review ethical board, 
(competent) ethics committee, ethical review 
authority, (medical) research ethics commit-
tee) have been created at institutional, local, 
regional, or national levels. Their mission 
is to determine whether the benefits of a 
research study outweigh its risks, appropriate 
participant consent procedures have been 
included, and the research design treats all 
groups of individuals fairly – e.g. no one 
is excluded from the research. Inspired by 
medical scientific journals, medical infor-
matics journals also increasingly require 
that investigators seek approval to conduct 
their research from an IRB for the study to 
be published (e.g. [4]).
Yet, there is variability across the “ethical 
traditions” of review boards. This variability 
is likely to be the result of different research 
fields (e.g., psychology, sociology, manage-
ment sciences), types of institutions where 
the research will take place (e.g. university, 
hospital), and regulations and laws applica-
ble in the country. Therefore, researchers in 
HOF within the medical informatics domain 
face different regulatory constraints and 
challenges, which is even more complex 
when studies cross national boundaries. 
As for other types of research (e.g. [5]), 
submission of HOF studies to an IRB can 
be resource intensive and time consuming, 
resulting in delays in the conduct of the 
study. Synchronizing review approval pro-
cesses with timelines of health information 
technology (HIT) implementations under 
study can be especially challenging – e.g., 
resulting in the technology being implement-
ed before permission to conduct the study 
has been obtained. 
Differences in rules and practices across 
IRB are often not justified. Best practices 
should be shared and implemented across 
the world, so that research benefits from the 
ethical review and is not negatively affected 
by the review process. Furthermore, if we 
wish to develop, implement, and evaluate 
transnational HIT, such as health informa-
tion exchange or patient-facing applications 
(patient travel beyond national boundaries), 
it is important to understand the rules and 
practices in ethics reviews in the field of 
HOF across the world. 
2   Aim of the Contribution 
and Collection of Testimonies
The aim of this paper is to perform a first 
exploration of practices related to IRB 
review in the context of HOF studies, their 
processes, constraints, outcomes, and advan-
tages in different countries and to provide an 
overview of best practices. With this goal in 
mind, IMIA’s Human Factors Engineering 
and Organizational Issues working group 
and EFMI’s Human and Organizational Fac-
tors of Medical Informatics working group 
contacted researchers in HOF in health tech-
nology with experience in involving human 
beings in their studies. These researchers 
were asked to report their experiences with 
IRB addressing the following topics: 
• Context of their experience with IRB in 
their country: which types of HOF studies 
should be submitted to IRB and to what 
extent? Are all studies concerned by the 
same process? 
• How do IRB operate? (submission pro-
cess, duration of the process, administra-
tive level of submission)
• What are the perceived advantages and 
drawbacks of the process? What is the 
perceived usefulness of the IRB review 
process for HOF studies and medical 
technology in general?
Researchers representing each country are 
not legal experts: they reported only their 
own experiences with IRB, which may not 
be an accurate representation of the regu-
lation applicable in their own country. The 
reports of each country were not intended 
to be exhaustive. Once the reports of each 
country were collected, similarities and 
differences between the IRB processes of 
each participating country were synthesized 
and discussed in order to highlight the best 
practices that should be shared and the com-
mon challenges.
3   Testimonies
Researchers from 11 countries accepted the 
invitation to contribute on this topic. Con-
tributions are provided by country, listed in 
alphabetical order. Appendix 1 provides a 
structured overview of the organization of 
the IRB review process, the planning of the 
process, and the challenges faced country 
per country.
3.1   Argentina (I. Jauregui, D. Luna, C. Otero) 
In Argentina, every study involving human 
participants is required to have an IRB ap-
proval prior to its initiation, and to deliver 
a follow-up documentation at least once 
a year until the study is completed. This 
process is regulated by a national law that 
although mainly focused on pharmacolog-
ical, diagnostic, and therapeutic protocols, 
also includes HOF studies in healthcare 
because of their intrinsic nature of studying 
human beings and healthcare. This national 
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law, which subscribes to the Declaration 
of Helsinki, delegates the surveillance of 
the protection of participants’ rights to the 
jurisdictional and institutional IRBs where 
the studies are carried out, by controlling 
and supervising the studies. Local ethical 
boards are autonomous: they decide about 
the approval of the studies, and they report 
to the jurisdictional (city) level only for 
statistical purposes.
IRBs have to be composed of multidisci-
plinary staff, evenly distributed across age, 
gender, and scientific and non-scientific 
members. The Hospital Italiano de Buenos 
Aires has an IRB that oversees all studies 
involving human subjects. It has a main 
procedure for approving protocols, in which 
investigators are required to present a study 
plan including a detailed methodology, 
clinical impact, data protection measures 
and funding sources, an informed consent of 
the participants to the study, a good clinical 
practices certificate, a letter of compliance 
with the Declaration of Helsinki, and the 
CV of the main investigator. The committee 
meets every 15 days, and in each session, 
it analyzes the new protocols and notifies 
the investigators of its decision, or asks for 
supplementary information or amendments 
for the protocol to be approved. This process 
takes around one to two months, and after 
approval investigators have to fill a form 
for the Health secretary that keeps track of 
all clinical protocols within its jurisdiction. 
The IRB has also an expedited procedure 
for studies that investigate aspects related to 
the clinical management of the organization, 
or for studies in which no sensitive data 
(i.e. demographics, diagnosis, vital signs, 
procedures, etc.) are handled, no therapeu-
tic or diagnostic instrument is used, and no 
possible harm is done to the patient. In this 
procedure, the statement from the commit-
tee is issued more rapidly. This procedure 
is sometimes used to get IRB approval for 
HOF studies, since no possible harm is 
done to participants, and findings help the 
organization to better engage with patients 
and staff information needs, and interaction 
with computer systems. 
We believe that legislation about ethics 
in HOF and generally in Health Informatics 
studies is lacking in our country. This type of 
studies arises different risks for participants 
than pharmacological or diagnostic test 
studies, and they should be regulated and 
monitored in a more specific way.
3.2   Australia (M. Baysari, W. Y. Zheng) 
As human factors researchers, we undertake 
studies that focus on understanding how 
work is done in practice and how information 
technology supports or hinders that work. 
For example, we have run multiple qualita-
tive observational and interview studies in 
hospitals where we examined how computer-
ized decision support influenced medication 
decision-making by doctors [6–9]. Although 
this research is non-interventional, to col-
lect and publish data of any kind requires 
researchers to obtain ethics approval. In 
Australia, this is a two-step process. Initially, 
ethics approval must be obtained from a Na-
tional Medical and Health Research Council 
(NHMRC)-approved Human Research Ethics 
Committee (HREC). These committees, 
which typically meet monthly, assess research 
to ensure it meets the requirements of the 
National Statement on Ethical Conduct in 
Human Research and is ethically acceptable 
[10]. Following HREC approval, site-spe-
cific governance approval must be obtained 
from each participating site (e.g. hospital). 
Site-specific assessment (SSA) allows the site 
to consider whether they have the capacity to 
conduct the research (e.g. physical resources, 
staff, insurance, and indemnity requirements). 
This can be particularly time-consuming 
when multi-site research is being done. If you 
are examining an IT system in three hospitals, 
you would need to obtain HREC approval 
once, but SSA approval three times. We see 
value in obtaining ethics approval to under-
take research, including non-interventional 
HOF research, but believe there are some key 
problems with the process.
Our biggest concern is with the lack 
of standardization in the application and 
approval process across sites and jurisdic-
tions. For example, additional forms are 
required for interstate researchers wishing 
to conduct research at sites in Queensland 
(Public Health Act) and Victoria (Victorian 
Specific Module).
Second, up until recently, the processes and 
application form required for ethics approval 
was dependent on the risk level of a project. 
Projects deemed to be at “low or negligible 
risk” were expedited through a streamlined 
process and the form required to be completed 
by researchers was shorter and simpler than 
the standard ethics form. Most HOF research 
comprises low risk research and so was 
processed through this expedited process. In 
2019, Australia’s national ethics form was 
revised and now a single application form is 
used for all projects, regardless of risk level. 
Finally, in order to gain access to a site 
for research, researchers are required to go 
through a series of authorizations and checks 
including vaccinations, police checks, and 
employment checks. Unfortunately, once 
a researcher is approved to collect data at 
one site, this does not carry across to other 
sites, even if in the same Australian State. 
New forms and checks are required to be 
completed at each data collection site.
Overall, we do not dispute the value 
of ensuring HOF research is undertaken 
ethically, posing minimal risk and inconve-
nience to participants (in our case, users of 
technology). Currently, the ethics approval 
process is viewed by HOF researchers as 
a barrier to completing research and can 
act as a deterrent to conducting multi-site 
research within public and private health 
organizations. This is problematic, as much 
can be learned from conducting research at 
multiple sites (i.e. context-specific factors 
influencing IT uptake or success). We are 
confident that the availability of a low effort, 
streamlined and consistent process for appli-
cations which pose a minimal risk to users 
and organizations, would be welcomed by 
all Australian HOF researchers.
3.3   Canada (C. Kuziemsky) 
In Canada, the Tri-Council Policy Statement 
(TCPS 21) is the national policy for ethical 
research involving humans. The TCPS 2 pro-
vides definitions for types of research studies 
and provides guidance for more complicated 
studies such as multi-jurisdictional research. 
There are three general categories of review. 
First is full board review, which is used for 
clinical trials or other intervention studies. 
Second is minimal-risk review, which is 
1 http://www.pre.ethics.gc.ca/eng/policy-politique_
tcps2-eptc2_2018.html
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done when the risk of adverse outcomes is 
no more than the risk from everyday life. 
Minimal risk is typically done by a delegated 
review where a selected set of review ethical 
board (REB) members review the file. Third 
is expedited review, done in cases when a 
project already has ethics approval from a 
TCPS 2-compliant Canadian university or 
hospital or if a project is using anonymized 
non-public secondary data. An example of 
this would be using anonymized data from a 
hospital. HOF studies involving human sub-
jects where data is being collected to answer 
a research question would always require 
ethics approval. Studies involving patient 
recruitment for observation or evaluation 
such as a usability study would be classified 
as minimal risk review and typically have 
turnaround times of up to six weeks. Expe-
dited review would take up to three weeks. 
However, while general guidelines for 
ethics approval are quite clear, the actual 
process of review can vary significantly 
depending on several factors. One factor is 
the affiliation of the researcher and where 
the study is being conducted. If a HOF 
researcher is affiliated with a University 
but doing research at a healthcare entity 
such as a hospital, ethics approval will be 
required from both the healthcare center 
(e.g. hospital) and the academic institution. 
The usual protocol is to first obtain ethics 
approval from the hospital and then submit 
for REB approval to the University where 
an expedited review of the ethics approval 
is done. Universities may sign a formal 
agreement with certain hospitals to better 
facilitate this two-stage application process. 
However, this two-stage process can lead to 
problems. Disputes can occur where ethics 
approval and conditions of it (e.g. how to 
recruit patients or conditions of a consent 
form) were approved by a hospital board but 
the University board requests changes to the 
protocol that contradicts what the hospital 
approval has described. Another factor is 
the healthcare context where the study is 
taking place. While hospital ethics boards 
should be knowledgeable of HOF studies, 
situations can arise where a healthcare region 
may have an ethics board that is not familiar 
with HOF studies and thus may have a hard 
time understanding the proposal or may be 
overly critical of the methods or approaches.
To make ethics approval more stream-
lined some Canadian provinces have a 
provincial ethics approval process that is 
a collaboration between universities and 
research sites such as hospitals or health 
authorities. An example of such a system is 
in British Columbia2. This system enables 
one streamlined ethics submission and can 
prevent conflicting reviews between boards. 
An overall challenge is that HOF studies 
are not well known across many Canadian 
healthcare facilities and universities, which 
can introduce problems during the review 
process. To overcome this issue, we need 
better promotion of HOF methods and 
approaches. 
3.4   Finland (J. Kaipio, M. Tyllinen) 
We have experience on two different types 
of studies involving ethical board review 
in Finland: health and social care workers’ 
experiences on their IT systems at a nation-
al level and patients’ experiences on their 
illness, care, and related digital services at 
a local level. These studies have different 
ethical review processes. 
In Finland, HOF studies fall under the 
ethical board review process if the require-
ments set by the Finnish Advisory Board on 
Research Integrity are met. These include 
e.g., no informed consent of subjects, sub-
jects under 15-year-old without parental 
consent, subjects exposed to security risks, 
or an intervention with impact on physical 
integrity. These ethical boards exist at the 
universities and in the Finnish national in-
stitute for health and welfare (THL). When 
hospitals are involved or when the research 
project comes under the Medical Research 
Act (national law), hospitals district’s ethical 
boards are responsible for the review. 
At Aalto university, the ethical commit-
tee is responsible for the ethical evaluation 
of the university‘s non-medical research 
projects in human sciences. Review is re-
quired in specific research configurations, 
but it can also be requested if the study’s 
publication forum, financier, or internation-
al partner requests it. The hospital district 
is the owner and supervisor of any research 
that studies their patients or in which 
2  https://researchethicsbc.ca/
members of their staff or data systems 
are utilized, or that is funded by research 
funds allocated by the district. In all cases, 
submissions are done via electronic systems 
and committees meet every month. At least, 
the following information is required when 
applying for an ethical review: a research 
plan including plan for conducting the re-
search, the list of the persons taking part in 
the research, and the privacy notice of the 
research for participants. 
In different fields of science and their 
related universities, ethical review boards 
have varying history and tradition, e.g., 
medical research has a long-established 
history compared to technical sciences. On 
the other hand, the recent changes in legis-
lation, particularly the European General 
Data Protection Regulation (GDPR), have 
complicated the study planning in general, 
especially when best practices are still lack-
ing. It seems that the organizations do not 
share a common understanding on what is 
regarded as personal data.
Based on our experience, the advantages 
of the ethical review process are: organiza-
tions have their own review boards, which 
are easy to reach, and processes are relatively 
quick. The process supports the planning of 
the details of the study including the privacy 
aspects of data storing and sharing. However, 
there are few concrete examples of how to 
apply these considerations in HOF studies, 
which makes the process cumbersome, bu-
reaucratic, and lengthy. It is also difficult for 
researchers to know in which circumstances 
an ethical board should be contacted and 
when it is the case, which one (especially 
when healthcare organizations are involved 
in the study as subjects). 
In Finland, the law considers medical 
research and not research ethics in general. 
Clearer national guidelines would be needed 
on whether HOF studies should have an ap-
proval from the ethical board or not. 
3.5   France (S. Pelayo) 
The Jardé law is a French law that governs 
„research organized and carried out on 
volunteers (either healthy or sick) with the 
objective of developing biological or med-
ical knowledge“ [11]. This law defines the 
categories of research and the functioning of 
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the network of national ethical boards called 
the committees of persons’ protection (CPP). 
Three categories of research are defined 
based on the level of risk to the subjects:
1. Interventional studies where the interven-
tion in treatment decisions and treatments 
differs from usual care;
2. Interventional studies presenting minimal 
risks and constraints when no pharma-
ceutical products are involved or only 
under their usual conditions of use. These 
studies are listed in a decision [12];
3. Observational studies when there is no 
intervention in treatment decisions. The 
researcher observes treatment and results 
in a systematic manner without changing, 
influencing, or interfering with diagnosis, 
treatment, or monitoring.
A decree has been published that defines 
the kinds of studies covered by the Jardé 
law [13]. “Experiments in human and social 
sciences in the field of health” are exclud-
ed. Consequently, it seems HOF studies 
do not fall within the scope of the Jardé 
law [14]. Yet, it is generally admitted that 
HOF research that might put the subjects 
at physical or psychological risk (e.g. ques-
tionnaire about suicidal ideations, stressful 
simulation) should require an ethical ap-
proval because they may be categorized in 
category 2 or 3. However, criteria to know 
whether a HOF study has to be submitted to 
a CPP are still subject to interpretation and 
discussion among researchers, institutions, 
and ethics boards. Submission of a protocol 
to a CPP is done through the platform of the 
French Healthcare Delivery Authority. This 
web platform randomly assigns submitted 
protocols to a regional CPP for appraisal. Re-
view times range from 45 days for research 
categories 2 and 3 to 60 days for category 
1. CPPs base their decision on the condi-
tions under which the researcher ensures 
the protection of persons, on the merits and 
relevance of the research project, and on its 
methodological quality.
For HOF studies not covered by the 
Jardé law (the large majority), there is no 
alternative regulation. Yet, if the researcher is 
affiliated to an institution (e.g., a university) 
that has its own local ethics board, s/he might 
need to get its approval. Those local boards 
are neither standardized in form nor in proce-
dure and have no statutory recognition (only 
CPPs are recognized); they “only” provide 
advices to their staff and support them in 
identifying ethical issues in their research 
projects and in thinking about their practices.
The Jardé law is a relevant initiative to 
frame research approval by proposing a 
common regulation and a one-stop-shop rec-
ognized interlocutor. Like any new system, it 
takes time to operate properly. The Jardé law 
and related decrees were written for tradi-
tional medical research and did not apply to 
every research case. Now, researchers need 
to be informed and trained to the Jardé law 
and related decisions. 
The Jardé law also broadened CPP scope: 
the number of protocols to appraise has 
grown, increasing the response time and 
delaying research projects’ implementation. 
The large majority of CPP members (physi-
cians, methodologists, pharmacists, lawyers, 
patients’ representatives, psychologists) are 
not informed about HOF studies and meth-
ods. This makes it difficult for them to make 
standardized and unbiased appraisals. It is 
also difficult for applicant HOF researchers 
to write “understandable” protocols. For the 
time being, practices in the CPP network are 
still quite heterogeneous with decisions not 
always harmonized.
3.6   Norway (E. C. Lehnbom, R. Pedersen)
Medical and health research conducted in 
Norway needs to be approved by an ethics 
committee if the aim is to trial new experi-
mental treatments, acquire new knowledge 
about health and disease, or if human 
biological samples or identifiable personal 
information (either collected by research-
ers or obtained from one or several central 
health registers) is to be used.3 Testing and 
evaluation of medical devices, defined as 
instruments or apparatus, produced to be 
used on people to diagnose, prevent, monitor, 
treat, or relieve disease, also require ethics 
approval. Research projects to evaluate how 
a new technology is being used (direct ob-
servations), to explore opinions (interviews) 
about new technologies, and quality assur-
3 REK Regional Committees for Medical and 
Health Research Ethics. Available at: https://
helseforskning.etikkom.no. Accessed 18 Oct. 2019. 
ance projects do not require ethics approval. 
Before submitting a complete ethics appli-
cation using the online portal, researchers 
can submit a request for assessment by the 
ethics committee. The request for assessment 
should contain information about the study 
aim, methods, analysis plan, requirement 
strategy, and data storage, and is also submit-
ted using the online portal. The committee 
then assesses the project and decides whether 
a full review is necessary or not. 
In addition to ethics assessment or 
approval, researchers also need to report 
projects to the regional PVO (Patient 
Protection Agent), which in turn inform 
the Data Protection Services (NSD)4 prior 
to commencing a research project if any 
personal information (such as a name on 
a consent form) is to be collected. There 
are no fees associated with the application 
for assessment or full review by the ethics 
committee, PVO, or NSD. 
Submission processes (ethics and data 
protection) are straightforward. The review 
process for ethics assessment is relatively 
quick, and usually done within one month. In 
our opinion, it is useful that an external com-
mittee reviews research projects and plans 
for data storage to minimize the risk of harm 
and breaches in privacy. It is important that 
the process is thorough yet quick, to achieve 
high compliance and to avoid unnecessary 
delays in starting research projects. 
3.7   Portugal (R. Santos, F. Leite, N. A. Silva)
In Portugal, all clinical research is regulat-
ed by Law No. 21/2014. Any systematic 
study designed to discover or verify the 
distribution or the effect of health factors, 
health status or outcomes, health and dis-
ease processes, or the performance and / or 
safety of interventions or services provided, 
is considered as clinical research. In the 
context of clinical research there are two 
main branches of work, clinical trials and 
clinical studies. Clinical studies may further 
be subdivided into studies with or without 
intervention. A study is considered without 
intervention when clinical practice is not 
altered by the study.
4 NSD Norwegian Centre for Research Data. Avai-
lable at: https://nsd.no/. Accessed 18 October 2019.
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All clinical research studies must be ap-
proved by the Competent Ethics Committee 
(CEC) which is responsible for ensuring 
the protection of patients’ rights, safety, and 
well-being for all patients involved in the 
research. Depending on the type of study, the 
CEC may be the nationwide Ethics Committee 
for Clinical Research (CEIC) for clinical trials 
and interventional clinical studies, or the local, 
hospital-specific, Ethics Committee for Health 
(CES) for clinical studies without intervention.
HOF studies generally fall under the 
classification of clinical studies without 
intervention, although the Law makes no 
special reference to these studies. The private 
group Luz Saúde, owner of the Hospital 
da Luz network where we operate, has a 
group-wide CES and a group-wide Clinical 
Research Commission (CIC), supporting its 
30 hospitals and clinics. The CIC assesses 
the clinical relevance and scientific quality of 
submitted clinical studies. HOF studies are 
evaluated by the CIC whenever the objective 
of the study is within the definition of clinical 
research. Additionally, studies should always 
be evaluated by the CES, even if the study is 
not considered to be clinical research, unless 
patient data is not used.
If patients are involved in a study, informed 
consent may also be required, and its clarity 
and completeness is evaluated by the CES. 
If personal data of participants based on the 
GDPR definition are also required, a Data Pro-
tection Impact Assessment (DPIA) should be 
performed. The responsibility for the devel-
opment of DPIA relies on the study sponsor. 
Hospital da Luz Learning Health (HLLH), 
a company within the Luz Saúde group re-
sponsible for all training and research, and 
the local Data Protection Officer (DPO) may 
assist the sponsor on the development of the 
DPIA, and will ultimately validate (HLLH) 
and approve (DPO) the DPIA.
The duration of these local assessments 
may vary. As a reference, in the Luz Saúde 
group, the CIC assessment will last two to 
four weeks, and the CES assessment will 
occur within a similar time frame.
If the scope of the study is by no means 
clinical and does not involve patient data, 
there is usually no need to involve the CIC 
or the CES, and what is required is the evalu-
ation by the HLLH and final approval by the 
Luz Saúde Executive Committee.
In Portugal, HOF studies that are part 
of the improvement of the socio-technical 
system that supports all care delivery, and 
specifically HOF studies related to medical 
technology, are still infrequent and unknown, 
which may initially hinder the evaluation 
process. Nevertheless, the increasing sub-
mission of HOF studies will improve knowl-
edge and awareness of these types of studies 
and will help in developing the discipline. 
It is our belief that the increasing visibility 
of these studies, also at the level of Ethics 
Committees, will not only raise the quality 
requirements for these studies to a level 
similar to other disciplines, but will also 
help to create evidence of their usefulness 
and positive impact.
3.8   Sweden (M. Hägglund) 
In Sweden, there is only one ethical review 
process that is applied to all research that in-
volves human subjects. The process is guided 
by the law on ethical review for research 
involving human subjects (2003:4605). 
This legislation applies to all research that 
involves physical interventions, methods 
that aim to affect the research participants, 
involves biological materials that can be 
traced back to a person, but also to research 
that includes handling of sensitive personal 
information (as defined in the European 
GDPR §9.1). Does this mean that HOF 
studies need ethical approval? Well, that 
would depend from case to case on whether 
or not they would handle sensitive personal 
information (e.g., on an individual’s health) 
or whether they may aim to somehow affect 
the subject physically or psychologically. 
In general, this means that a study of 
healthcare professional’s use of IT, organiza-
tional studies and usability studies involving 
healthcare professionals do not require ethical 
approval according to the current Swedish 
legislation. If patients are involved, we howev-
er need to consider whether any health-related 
data would need to be gathered; if so – ethical 
approval would be required. This could be the 





mock data and you document information 
about the study participant’s current or past 
health issues, or their contact with health-
care. Therefore, in most health informatics 
research, ethical approval is sought whenever 
patients will be involved in the study, as sen-
sitive personal data regarding their health will 
likely be documented. 
All ethical reviews are handled by the 
Swedish Ethical Review Authority6, which 
started on the first of January 2019. The work 
is still divided between six different regions 
(Göteborg, Linköping, Lund, Umeå, Uppsala 
and Stockholm). Each regional office has 
at least one division for reviewing medical 
research and one division for other research. 
Each division has 10 representatives with 
scientific background and five representa-
tives of the public. The chair of a division 
should be or has been a judge. 
When you apply for ethical approval, 
you send your application to the Ethical 
Review Authority, and it will be assigned to 
the region and division they consider most 
appropriate. The application is therefore very 
similar for medical research as it is for other 
types of research. An application for ethical 
review costs 5000 SEK (515 USD), or 16000 
SEK (1648 USD) if more than one research 
institution is involved. If at a later point, an 
ethical approval needs to be changed (e.g. 
addition of a new study site, or inclusion of 
more study participants) a new assessment 
will be made for a cost of 2000 SEK (206 
USD). An ethical application will usually be 
handled within 60 days of submission, and 
the applicant will have the results within two 
weeks of the decision. 
The ethical review process in Sweden 
clearly takes its starting point in medical 
research. It is often unclear what aspects 
of a study focusing e.g., on the usability of 
an app or medical device will need ethical 
approval, and there exists very little guidance 
for researchers within this field. Therefore, 
we often end up applying for ethics review 
just to be on the safe side and are often told 
that ethical approval is not required for this 
study. Considering the costs and extensive 
documentation required to apply for ethical 
approval, it sometimes creates barriers for 
6 Etikprövningsmyndigheten: https:/ /et ik-
provningsmyndigheten.se 
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important research that needs to be done. An 
expedited application process for projects that 
will not expose study participants to great risk 
would be helpful, or a pre-application process 
to help determine whether a project will be 
exempt from applying for ethical approval.
The application process is also poorly 
designed to meet requirements of more 
design-oriented research, where formative 
evaluations, scoping interviews, and focus 
groups or workshops are needed. Especially 
as we see an increased interest in patient par-
ticipation, patients as research partners, and 
patient-driven research, we need to consider 
how these types of research formats will 
affect the ethical approval process. Ethical 
reviews will continue to be just as important 
but may require a different format and an 
understanding of these types of research in 
the ethical review divisions. Finally, how 
we guide researchers in interdisciplinary 
research projects that involve both needs 
analysis, design, formative evaluations, and 
clinical testing is still not clear.
3.9   The Netherlands (L. van Velsen,         
S. Jansen-Kosterink) 
In the Netherlands, ethical considerations re-
garding medical research involving humans 
and the procedures for requesting permission 
to conduct these studies, are described in the 
Dutch Medical Research Involving Human 
Subjects Act (WMO)7. Research is subject 
to the WMO if the following criteria are met: 
(1) it concerns medical scientific research 
and (2) participants are subject to procedures 
or are required to follow rules of behavior. 
If a study is subject to the WMO, it must 
undergo a review by an accredited Medical 
Research Ethics Committee (MREC). These 
MRECs are typically hosted by large, aca-
demic hospitals.
HOF studies are, normally, not subject to 
the WMO if people voluntarily participate 
and if the study does not infringe upon the 
physical and / or psychological integrity of 
participants. This is often the case for stud-
ies such as usability tests of a new eHealth 




added value of a technology is discussed. 
To be sure that our HOF studies do not fall 
under the scope of the WMO, the authors 
normally ask an accredited MREC to check 
this assumption. If so, the MREC provides 
an official letter, stating that the study is not 
subject to the WMO. This check requires to 
submit the study protocol, the information 
letter for the subjects, and the informed 
consent form. After submission, this official 
letter is received within a week. In any case, 
each study will be conducted according to 
the principles of the Declaration of Helsinki: 
all subjects must provide informed consent 
before participation, and their data will be 
stored and analyzed anonymously. 
If, for some reason, a HOF study does 
fall within the WMO, a full application for 
conducting the study must be sent to an 
MREC. For general (medical) research, that 
is, no research with a medicinal product, 
a so-called “reasonable timeline” of eight 
weeks applies. This means that the MREC 
has a maximum of eight weeks to reach a 
decision, unless the MREC gives notice that 
more time is needed, including an alternative 
timeline. Conducting a study that falls under 
the WMO without a positive decision from 
an accredited MREC is an offence.
The Netherlands has strict rules for re-
search with human subjects and this makes 
it clear for researchers how to handle ethical 
review. Furthermore, the review of your 
medical or HOF study by an accredited 
MREC is very valuable. It makes one reflect 
on the benefit of your study against patient 
burden, so that the study protocol can be 
improved in order to comply with ethical 
principles. However, MRECs mainly review 
general medical research and have less ex-
perience with HOF studies. In some cases, 
this make it difficult for them to review these 
studies properly. The letter of exception that 
is often granted for HOF studies, makes it 
easy for researchers to publish their work, 
as it serves as an official statement about a 
study’s ethical compliance.
3.10   United Kingdom (V. Lichtner) 
I have been doing research on implemen-
tation and use of IT in clinical settings in 
England (UK) for over ten years, such as 
evaluations of IT implementations in doc-
tors’ clinics in the community and hospitals 
in the National Health Service (NHS). This 
HOF research was conducted with quali-
tative studies aimed at understanding how 
technology responds to clinicians’ informa-
tion needs in local sociotechnical contexts. 
Any research conducted in the NHS 
requires approval by an NHS Research 
Ethics Committees (REC) and approval by 
local research governance (RG) bodies (e.g. 
hospital research units). Over the years, 
applications to NHS REC in England have 
been streamlined, leading to a centralized 
online submission through an Integrated 
Research Application System (IRAS), man-
aged by the NHS Health Research Authority 
(HRA)8. HOF studies are usually classified 
as ‘low risk’ and a simplified application 
form is generated by the system, compared 
to the one suitable for clinical trials where 
risks of intervention to participants may be 
considerable. At the time of submission, 
IRAS suggests ‘the first available slot’ of a 
REC – anywhere in England - suitable for 
the type of study submitted. Researchers 
are not bound to choose ‘the nearest REC’; 
choosing ‘the first available slot’ may speed 
up the approval process. 
In the context of the studies I conduct-
ed, obtaining local RG approval has been 
much more challenging. The process was 
often not standardized. Some RG bodies 
required contracts in place between the 
University and the NHS organization where 
the research was taking place. It often 
involved communication with staff locally 
to track the status of the application, and 
what would be needed to move it forward, 
but identifying the person to speak to was 
difficult. Receiving RG approval at the level 
of the hospital, or health authority, was also 
not sufficient to guarantee access to single 
clinical wards or GP clinics – each had to 
be negotiated separately. This made multi-
site studies incredibly difficult and time 
consuming to set-up, hindering research. 
For example, in the case of the evaluation of 
the electronic transmission of prescriptions 
in primary care clinics, we had to apply to 
different local authorities where the clinics 
were located, each taking months to re-
8 https://www.hra.nhs.uk/approvals-amendments/
what-approvals-do-i-need/
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spond. While the roll-out of the technology 
across England followed an agile approach, 
we were unable to be present on the sites at 
the same speed to observe activities [15].
The HRA has recently centralized the 
local RG applications, as part of the appli-
cation to REC9. However, the researcher is 
still responsible for updating local sites of 
progress. Guidance provided on how to fill in 
the HRA application to satisfy local approval 
feels overwhelming10. There is also varia-
tion in how HRA administrators interpret 
the GDPR – anecdotally, some are placing 
unrealistic burdens of patient consent on 
researchers in clinical areas where patient 
information is otherwise displayed publicly 
on whiteboards.
A further stumbling block is that the 
REC-approved study protocol may place 
unexpected barriers on the research as it 
unfolds in practice. HOF qualitative research 
needs to be ‘open to the unexpected’. For 
example, understanding technology for 
medication in a clinical ward may take the 
researcher to also investigate dispensing 
activities in the hospital pharmacy. If this 
is not foreseen in the initial application, the 
researcher must stop the study and submit an 
amendment to REC, losing valuable time and 
perhaps valuable opportunities for gaining 
insight into current work practices.
3.11   United States (B. Lesselroth, J. Homco) 
Our team has nearly 20 years of collective 
experience working on informatics projects 
at various US institutions. We have partici-
pated on intercollegiate, governmental, and 
industry projects, affording us the opportu-
nity to work with regulatory oversight bodies 
at the federal, state, and private levels. Our 
projects tend to be operational, addressing 
quality improvement (QI), HIT implemen-
tations, or user experience (UX) evaluation. 
Christine Grady wrote that medical 
research and quality improvement occupy 
a continuum ranging from passive obser-
vation to controlled experimentation [16]. 






ducting HOF studies – particularly when 
evaluating users interacting with HIT. This 
fact notwithstanding, we believe infor-
maticians have an obligation to evaluate 
HFO impact with objectivity. This requires 
rigorous standards for data handling and 
independent review to protect patient and 
staff safety. Therefore, we self-govern by 
writing protocols for every project, ensur-
ing a high level of methodologic rigor and 
a consistent process for data handling. As 
per institutional expectations, we solicit a 
review from the IRB (either a full review or 
an expedited process, as described below). 
Furthermore, we notify our IRB office of 
any projects involving human subjects that 
will likely result in publication of findings 
that may contribute to a cumulative knowl-
edge base. 
The University of Oklahoma rules and 
regulations governing research operation-
alize at a local level federal regulation 
enforced by the US Department of Health 
and Human Services, the US Food and 
Drug Administration, the US Department 
of Veterans Affairs, and the US Department 
of Defense. The University also upholds the 
Federal Health Insurance and Portability 
and Accountability Act (HIPAA) for the 
protection of patient health information 
and the Oklahoma state laws pertaining 
to protections of vulnerable populations 
including emancipated minors and cogni-
tively impaired individuals. Criteria used 
for defining and policing research are con-
sistent with federally published standards 
and are similar between institutions (US 
Code of Federal Regulations 45FR.46.102; 
Bailey, Hastings Center Report, 2006). 
We submit all projects – including HOF 
work – to our institutional IRB well in ad-
vance of any data collection. Many IRBs, 
including at the University of Oklahoma, 
offer an expedited pathway for quality im-
provement efforts, educational programs, 
and non-experimental technologies. Typi-
cally, these studies do not include participant 
consent forms, different exposures, random-
ization, or a control group. The expedited 
process permits IRB members to pre-screen 
projects and allow low-risk ones to bypass 
the normative IRB review and governance 
system. The process begins with completion 
of a “determination of research” checklist 
and provision of a project description that in-
cludes methods, types of data to be collected, 
and anticipated deliverables. The checklist 
includes criteria to help reviewers estimate 
risk and disambiguate quality improvement 
activities – including HOF work – from 
traditional research. At a high level, research 
tests hypotheses to develop generalizable 
knowledge, whereas quality improvement 
and HOF apply generalizable knowledge 
to “quickly” improve health delivery. The 
IRB at the University of Oklahoma School 
of Community Medicine typically responds 
to an application within two to four weeks.
There are several important strengths and 
limitations of the current IRB processes. 
Strengths include: (1) a single intake path-
way and administrative infrastructure; (2) a 
clear set of criteria and definitions that can 
inform protocol development; (3) a stream-
lined set of monitors and documentation 
for QI and HOF work; and (4) the presence 
of a regulatory framework that protects 
stakeholders and promotes a high level of 
academic rigor. 
Weaknesses include: (1) lack of specific 
guidance for evaluation of HIT including 
electronic health record configurations or 
modules; (2) ambiguity surrounding par-
ticipation of clinicians or trainees when 
participation is mandatory as a component 
of care; (3) lack of administrative stake-
holders with experience conducting QI or 
UX work (leads to difficulty understanding 
proposal, methods, scope, and impact); (4) 
the additional time required to determine 
the single IRB of record when multiple 
agencies are participating on a project; 
(5) an often lengthy and bureaucratic 
process (frequently impacted by personnel 
shortages); (6) a commonly held, but false 
dichotomy between “research” and HOF 
work; (7) organizational opposition to the 
use of “research language” in HOF and QI 
applications; and (8) the need for language 
defining “generalizability” of f indings 
(point of contention when we seek to pub-
lish findings or lessons learned about the 
design, implementation, and evaluation). 
To this final point, we contend that QI and 
HOF works make important contributions 
to our theoretical frameworks and under-
standing of QI methods and implementation 
effectiveness.
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4   Synthesis and Discussion
This study explored the differences, chal-
lenges, and best practices of HOF of medical 
informatics (HOFMI) research projects with 
respect to ethical board review processes in 
11 countries. From the testimonies above, 
key findings emerge that indicate shared 
challenges that researchers face in ethical 
board review for HOFMI studies. Table 
1 synthesizes these challenges and offers 
an overview of proposed solutions recom-
mended by participating HOFMI researchers 
based on the needs and experiences within 
Table 1   Synthesis of the challenges faced by HOFMI studies and some proposed solutions. Countries that specifically described challenges or proposed solutions are indicated between brackets. Note that not all countries that 
pointed to a challenge proposed a solution. Conversely, some countries proposed solutions to challenges that they did not face. There is no one-to-one correspondence between expressed challenges and proposed solutions; 
some challenges require the application of several solutions and some solutions correspond to several challenges.
their research. It must be stated that the 
themes presented in the table are not ex-
haustive; some countries might experience 
the same concerns, but they might not have 
referred to this in their testimonies. 
A major concern mentioned by HOF 
researchers relates to ambiguous ethics legis-
lation and guidelines. From a legal standpoint, 
the need for protecting the safety and privacy 
of participants in research projects is specified 
in the national laws of the country where the 
research is carried out. The majority of the 
testimonies however describe that knowing 
whether HOF studies need IRB approval 
remains open to debate because these laws 
do not specify how to interpret them when 
dealing with HOF research in healthcare. To 
ensure that research protocols consider rele-
vant ethical dimensions, HOF researchers are 
prone to take the safe route and submit their 
research protocols to the IRBs for review. In 
a practical sense however, not all HOF studies 
benefit from full IRB review. For studies that 
are generally considered with ‘no’ or ‘low’ 
risk to participants, such as usability testing 
of an eHealth application with healthy and 
willing participants, a shortened and more 
efficient review process would be better 
Challenges for HOFMI studies
Legislation about HOFMI and ethics
 Legislation is unclear, undefined, and subject to interpretation; lack of clarity with respect to what 
projects need to be reviewed leads to a cumbersome and disproportionate reviewing process. [Argentina, 
Australia, Finland, France, Sweden, United States] 
 Review processes are the same regardless of risk level: criteria to define whether a HOFMI study is of 
low or high risk regarding ethical review are lacking. [Argentina, Australia, Sweden]
 Ethical review processes are medical/evaluation-oriented and are not adapted to (patient-centered) IT 
design studies. Specificities of HOFMI research protocols do not fit the ‘known’ ethical review process. 
[Sweden, United Kingdom]
IRB reviewing process
 Inconsistencies in the ethical process and jurisdictional differences between sites are barriers to the 
performance of (multisite) HOFMI research. [Australia, Canada, United Kingdom]
 Repetition of the ethical process across multiple sites is inefficient and makes it difficult for researchers 
to work in line with the fast developments observed in the medical/technical field. [Australia, Canada, 
United Kingdom, United States]
Specific issues
 Application of GDPR in relation with HOFMI studies encounters difficulties in interpretation and 
relevance. [Finland, United Kingdom]
 Cost and extensive documentation represent a barrier. [Sweden]
Awareness of HOF studies
 Lack of awareness and lack of knowledge about HOF studies by IRB members lead to problems and 
delays in the reviewing process. [Canada, France, Portugal, The Netherlands, United States]
 HOF researchers, specifically from the technical sciences, may be unaware of IRB approval. Little 
guidance is provided. [France, Sweden, United Kingdom, United States]
Proposed solutions
 Legislation to specify at a national level if HOF studies need or not approval from 
ethical boards. [Finland]
 Regulate and monitor HOFMI studies in a way more specific/suitable to these 
studies. [Argentina]
 Elaborate principles to define the level of risk of HOF research (high risk/low risk).
 Define an expedited ethical review process for low risk studies, e.g., through a 
pre-application process. [Argentina, Sweden]
 Umbrella’ partnership agreements between universities and healthcare centers to 
facilitate local approval processes. [Canada, United Kingdom]
 A low effort, streamlined review process. [Australia]
 A standardized approach and guidance on how the GDPR applies to different 
types of studies [United Kingdom], supported by an external committee reviewing 
research projects to minimize the risk of privacy breaches. [Norway]
 Review process free of charge. [Norway]
 Better promotion of HOF methods and approaches. [Canada, France, Portugal, The 
Netherlands, United States]
 Increase HOF knowledge for ethical review board members. [France]
 Provide concrete examples of applying ethical considerations in HOF studies. 
[Finland, France, United States]
 Develop guidelines for HOF researchers on how and when to apply for ethical 
review. [Australia, France Norway Sweden, United States]
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suited. HOF researchers from Argentina, 
Norway, The Netherlands and the United 
States have a pre-application ethical review 
process available in their country. This may 
consist of pre-screening to determine if the 
research protocol needs approval, which may 
offer researchers an exemption from ethical 
review. Publishing journals require a study 
to comment on their ethical compliance; 
a letter of IRB review exemption would 
provide researchers with a way to respond 
to journals’ requirements. Furthermore, in 
determining the risks associated with a study, 
an expedited review process may help bypass 
the extended IRB review that is needed for 
higher risk studies. Such an expedited process 
may enable HOF research to better align to 
the quick technical developments and tech-
nology implementation processes that are 
the subject of the study. Having a separate 
shortened ethics review process would not 
only facilitate HOF researchers, but it would 
also lower IRB administrative burden. On 
the basis of these testimonies, we propose 
in Figure 1 a best practice IRB ethics review 
process for HOF studies which may serve as 
a model to improve IRB processes. 
Australia however, has revised their na-
tional ethics form in 2019 and instead of an 
expedited process now a single application 
form is used for all projects, regardless of 
risk level. This development indicates the 
need to define clear international criteria 
when full IRB review is indeed needed and 
when not. A private initiative such as from a 
medical product development company may 
provide a first approach to determine the risk 
level of HOF studies, but this needs further 
scientific foundation [17]. 
A second main concern relates to perceived 
inefficiency and inconsistency in the ethics 
reviewing processes due to variability in ethics 
committees’ processes between institutional 
and local IRBs. Often, a two-step process in 
which either a national and local level board 
review or a university and hospital agreement 
is required to guarantee access to single re-
search sites. A HOF researcher hence needs 
to liaise with local sites and is in constant need 
of ‘getting people on board’ while explaining 
the relevance and benefits of the study. This 
is time consuming for HOF researchers and 
may pose a significant hindrance to multi-side 
studies. To tackle this, umbrella partnerships 
are proposed to quicken and streamline these 
processes. In addition, a smaller but still 
important barrier is mentioned with regard 
to the experienced uncertainty around the 
interpretation and use of the EU GDPR [18]. 
When research organizations do not share a 
common understanding on what is regarded 
as personal data, this complicates the study 
planning. More guidance is therefore also 
needed to adequately interpret the GDPR for 
different types of studies. 
A final central theme in the majority of tes-
timonies is the unawareness of IRB members 
with the goals and standard practices of HOF 
research. IRBs are from a historical perspec-
tive more familiar with clinical trials and other 
quantitative study designs involving human 
subject research and experience variability 
in reviewing outcomes of protocols in other 
types of research areas [19]. HOF research 
is characterized by often smaller scale, less-
strict and more qualitative research designs 
that need high flexibility and for which 
standard (bio)medical study designs are often 
unsuitable [20]. As a result, the reviewing time 
of the board may be delayed until the study 
approach and design can be appraised appro-
priately. Reviews may be then also subject to 
variation depending on the expertise of the 
board members. Other concerns with regard 
to IRB review processes regard the necessity 
for a systemic improvement that needs to in-
clude better standardization of review practic-
es, enhanced training for IRB members, and 
accreditation of review boards [21]. With the 
continual rise of technical innovations imple-
mented in healthcare and associated studies, 
the need for IRB members to receive adequate 
training in reviewing these types of studies is 
becoming imperative. Visa versa, studies in 
the medical technology industry also need to 
become more aware of the need for ethical 
approval and the procedures involved. 
This study has some specific strengths 
and limitations. Our unstructured survey 
approach allowed contributing researchers 
to highlight issues they considered most 
relevant when facing current IRB processes 
Fig. 1   Schematic representation of a proposed two-step review process. On the left, the pre-application process would inform the researcher whether her/his study must be submitted to an IRB and what is the level of risk 
for study participants. A letter of exemption is given to the applicant if his/her study does not have to undergo a complete review process. On the right, the researcher submits the full version of the protocol to the IRB for an 
expedited process (in case of low risk studies) or for a regular process (in case of high risk studies). 
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in their country. HOF research practices 
however differed in organization, e.g., from 
a national level to a more local level, which 
limited the comparability of the contribu-
tions. It was however not our intention to 
provide an exhaustive view on (dis)similar-
ities but rather to take a first step in obtain-
ing insight on what impedes or facilitates 
good IRB practices for HOF studies across 
countries. Topics reported were found to be 
largely similar or equivalent, highlighting the 
generic nature of issues faced, and indicating 
the high validity of the synthesis. 
5   Conclusion
Overall, it may be stated that not all HOF 
research needs ethical approval and that 
going through a full IRB review process 
may result in inconvenient consequences in 
performing the study. For that reason, HOF 
research needs more guidance and greater 
clarity in which research protocols need IRB 
approval to demonstrate their compliance 
to AMIA’s code of professional and ethical 
conduct. For this, our HOF community will 
start with gaining consensus on criteria 
that define low and high-risk HOF studies 
at an international level. Best practices as 
described within this paper substantiate 
the proposed pre-application and expedit-
ed IRB review process for ethical review 
of low risk HOF studies. Enhancing IRB 
processes in such a way would not only be 
beneficial to HOF studies but would also 
lower the administrative pressure on IRBs. 
In addition, by providing an overview of 
relevant evidence-based HOF study designs 
and better promoting these, knowledge and 
awareness for HOF studies will increase 
which in turn will help in developing the dis-
cipline. This overview may also inform the 
development of a (online) training program 
for IRB members on HOF study approaches 
and methodologies, such as qualitative and 
mixed methods studies, iterative user design 
research of health technology combined 
with, for example, design thinking, rapid 
engineering, and user testing approaches. 
Such guidance for IRBs is needed in this 
age of innovative health technology so that 
the correct ethics dimensions are considered. 
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